首页>
外国专利>
Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
展开▼
机译:皮下注射抗IL-6受体抗体治疗青少年特发性关节炎
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
展开▼